中外医学研究2024，Vol.22Issue(6)：159-164,6.DOI:10.14033/j.cnki.cfmr.2024.06.040
GLP-1RA药物司美格鲁肽的临床研究进展
Clinical Research Progress of GLP-1RA Drug Semaglutide
洪毅颖1
作者信息
- 1. 浙江大学医学院附属邵逸夫医院 浙江 杭州 310016
- 折叠
摘要
Abstract
Semaglutide is a polypeptide hypoglycemic drug,it has stood out in its glucagon-like peptide-1 receptor agonist class because of its safety,wide indications,long half-life and other advantages,and has become a hot spot in clinical research.This article provided a reference for Semaglutide's clinical application and reasonable selection by analyzing its safety and introducing the research progress in various aspects such as hypoglycemic,cardiovascular protection and weight loss.关键词
司美格鲁肽/胰高糖素样肽-1受体激动剂/2型糖尿病/研究进展Key words
Semaglutide/Glucagon-like peptide-1 receptor agonist/Type 2 diabetes mellitus/Research progress引用本文复制引用
洪毅颖..GLP-1RA药物司美格鲁肽的临床研究进展[J].中外医学研究,2024,22(6):159-164,6.
